The Right's Psychedelic Pivot: Who's Actually Funding Psychedelic Legalization

Peter Thiel does not do anything for vibes. The PayPal co-founder and Palantir architect, who has spent the better part of two decades funding surveillance infrastructure, right-libertarian think tanks, and the systematic dismantling of the administrative state, does not sit on a therapy couch and wonder if psilocybin might help him reconnect with his inner child. When Thiel's Founders Fund takes an interest in a sector, the question worth asking is not "why psychedelics?" It is "what does the market look like from the other side of FDA approval?"

On April 18, 2026, Donald Trump signed an executive order to "dramatically accelerate access to new medical research and treatments based on psychedelic drugs." The order directed the FDA to fast-track review of compounds already holding Breakthrough Therapy designation and expanded Right to Try protections — a legal mechanism previously reserved for terminally ill patients seeking unapproved drugs — to cover people with serious mental health conditions. The White House framed it under the MAHA banner, Robert F. Kennedy Jr.'s Make America Healthy Again initiative, which has become a useful umbrella for a particular kind of deregulatory health policy that sounds like wellness and functions like market-clearing.

The psychedelic media largely celebrated. The headlines read like the end of something. "End of Prohibition." "A New Era for Mental Health." What the coverage mostly did not ask is who benefits from a newly opened regulatory fast lane — and who already has their cars lined up at the entrance.

What Changed, and When

The shift did not happen overnight, which is important to keep in mind if you are trying to figure out what it means.

In 1970, Richard Nixon declared psychedelics public enemy No. 1 and placed them in Schedule I — the most restrictive category of federal prohibition, reserved for substances with no accepted medical use. Fifty-six years later, a president from the same party signed an Oval Office executive order to accelerate research into LSD, peyote, and MDMA. The ceremony was formal, the optics deliberate. That span — Nixon's Schedule I designation to a Republican president hosting a White House ceremony for psychedelic research — is the actual story. Everything else is detail.

The politically safe entry point was ibogaine. The psychedelic, derived from an African shrub and traditionally used in healing ceremonies, has shown striking results treating opioid addiction and PTSD in veterans. This population had been advocating for it for years before any politician was willing to listen. Ibogaine remains Schedule I, but championing it for veterans dealing with addiction is difficult to oppose in either party. Congressional "psychedelic caucuses" quietly formed around this framing. The language shifted from "drug legalization" to "mental health innovation." This is how a fringe position becomes an acceptable investment thesis— slowly, through a population no one wants to say no to, and then with an executive order.

The investment money had been accumulating for years before the politics caught up. By the time the Trump EO landed, the Breakthrough Therapy designation — an FDA classification meant to accelerate development of drugs that show substantial improvement over existing treatments — was already held by a small number of well-capitalized companies. Breakthrough Therapy status is not handed out broadly. It requires resources to run the kinds of trials that qualify. The companies that have it are, by definition, the ones that could afford to get there.

The April 18 order does not create new access to psychedelics for everyone. It creates a faster lane to approval for compounds that already hold specific federal designations. The companies that hold those designations benefit specifically. The broader research community does not.

Follow the Money

Antonio Gracias runs Valor Equity Partners. He is also one of Elon Musk's longest-standing financial associates — a Musk lieutenant and an investor in SpaceX, Tesla, and several other ventures in the Thiel-adjacent corner of the tech-libertarian ecosystem. Gracias and Thiel are among the named figures that analysts tracking psychedelic industry investment have identified as key backers of the sector's political push. Neither is a mental health researcher. Both are people who understand what happens to valuations when a regulatory pathway shortens.

The existing legal template for what a fully medicalized psychedelic market looks like is already available for study. It is called esketamine. Sold by Janssen under the brand name Spravato, esketamine is a nasal spray derived from ketamine, FDA approved in 2019 for treatment-resistant depression. It is administered in certified clinical settings. It costs upward of $800 per session. It requires insurance preauthorization. It is not something you take at home. It is not something you take in a ceremony. It is a proprietary delivery format, controlled at every point in the supply chain, generating revenue at every step.

This is the template. Not the commune. Not the ceremony. Not the research university. The clinic, the proprietary compound, the insurance billing code. The business model behind making health a market has been refined over decades, and what it reliably produces is a version of a thing that costs a great deal more than the thing it replaced, is administered by credentialed professionals in controlled settings, and generates recurring revenue.

The August 2024 FDA rejection of Lykos Therapeutics' application for MDMA-assisted therapy for PTSD is instructive here. Lykos — formerly MAPS PBC, the nonprofit that spent decades running rigorous clinical research on MDMA — had the most clinically validated psychedelic therapy in the pipeline. The FDA rejected it on grounds of clinical trial design flaws and concerns about therapist misconduct, not on efficacy. The rejection was not primarily about whether MDMA works. The rejection collapsed Lykos's valuation anyway.

Meanwhile, investment continued to flow into compounds that are less clinically validated but more IP-protected. The FDA rejection of the most thoroughly researched psychedelic therapy did not slow the investment thesis. It may have clarified it: what matters is not which compound works best. What matters is which compound you own the patent on when the regulatory window opens.

There is a related claim worth noting, made by researchers tracking the ideological dimensions of this investment surge: that figures connected to Palantir and the broader tech-right ecosystem have framed psychedelics not as liberation tools but as instruments for what has been described as "killing the woke mind virus" — meaning, resetting belief systems rather than expanding them. Whether you find that reading persuasive or not, it is a useful reminder that the people funding this are not doing so because they had a transformative experience and want to share it. They have a specific idea of what the transformation should produce.

The accusation circulating in psychedelic research circles is "oligarch monopolization of psychedelic medicine." The concern is not that psychedelic therapy will not become legal. It is that it will become legal in a form that looks like esketamine: proprietary, expensive, clinic-administered, and controlled from seed to session by whoever got to the IP first.

What This Means for the Science

The original psychedelic research movement — the version that operated out of universities and nonprofits for the past two decades — was not primarily interested in IP. MAPS, the organization that eventually became Lykos, spent thirty years running placebo-controlled trials on MDMA and publishing the results. The goal was FDA approval for a therapy that could then be practiced by trained therapists, ideally in a way that was accessible rather than extractive.

That model is now under pressure from a different direction. When HHS staffing decisions reflect "psychedelic industry evangelists" — a characterization made by researchers observing the regulatory environment — the question of who controls the clinical pathways becomes a question about which science gets validated and which gets sidelined. The FDA Breakthrough Therapy designation determines whose research gets fast-tracked. The companies with that designation are the ones with the capital to run the qualifying trials. The fast lane created by the EO specifically accelerates their path.

This does not mean the science is wrong. Psilocybin and MDMA have shown genuine clinical promise in peer-reviewed trials. The question the EO raises is not "do these compounds work?" It is "who decides how they're delivered, at what price, through which channels, and with which compounds getting priority when the fast lane only has so many slots?"

What legal scholars flagged immediately after the April 18 signing was the novel legal expansion embedded in the order. Right to Try has historically applied to terminal illness — the legal premise being that someone with no other options should be able to access an unapproved drug. Extending that framework to serious mental health conditions is a significant conceptual jump. Mental illness is not terminal in the same legal sense. The expansion creates a new category of access that has not been tested in court and that, by design, bypasses the normal FDA approval process for the compounds that benefit from it. The beneficiaries of that bypass are, again, the companies that already hold Breakthrough Therapy designation.

The Political Pivot Explained

The question everyone keeps asking is why conservatives changed their minds about drugs. The premise of the question is slightly off. The same political coalition that ran the War on Drugs for fifty years has not decided that drugs are good. It has decided that a specific, highly regulated, proprietary, clinical, expensive version of psychedelic therapy is a health product worth accelerating — and that the regulatory apparatus that would normally slow that acceleration is an obstacle worth removing.

Worth noting in this context: Trump is a lifelong teetotaler who does not drink and has never used drugs. He signed the Oval Office order championing LSD, peyote, and MDMA. Make of that what you will, but it is worth sitting with for a moment. The man most identified with the phrase "law and order" in American politics did not arrive at this position through personal experience with altered states. He arrived at it through a political coalition that found its interests aligned with a particular vision of what psychedelic medicine should become.

The War on Drugs was always partly an economic project: it controlled certain markets and criminalized certain communities while leaving other markets and communities untouched. The psychedelic pivot follows a similar logic. The compounds being championed are not street drugs. They are patentable molecules administered in clinical settings by licensed professionals, billed to insurance, and reviewed by a federal agency that now has a faster lane for the companies that got there first.

The libertarian tech right's interest in psychedelics fits neatly into its broader investment in deregulation as a market-creation strategy. Remove the regulatory barriers, let the well-capitalized players through the gate first, then watch the market structure solidify around the companies that were already in position. This is not a theory about what might happen. It is a description of how every previous round of healthcare deregulation-as-innovation has played out, from specialty pharmaceuticals to medical devices to telehealth.

The psychedelic EO was not an isolated move. The same week, the Justice Department loosened restrictions on medical marijuana — part of a broader drug policy pivot that is less about changing values than about opening markets the current coalition has positioned itself to dominate.

The framing of the EO under MAHA is worth noting in that context. RFK Jr.'s anti-establishment health rhetoric has been absorbed into an executive action that does not challenge pharmaceutical IP. It accelerates it. The "Make America Healthy Again" initiative, in this instance, produces a policy that benefits the companies that own the designation and the investors who backed them, which is not the same thing as making America healthy. It is the same thing as making a market.

Key Facts

• April 18, 2026: Trump signs executive order to "dramatically accelerate" psychedelic therapy research in a formal Oval Office ceremony, expanding Right to Try protections to serious mental illness and directing faster FDA review of Breakthrough Therapy-designated compounds.
• Nixon declared psychedelics "public enemy No. 1" in 1970 and placed them in Schedule I. Fifty-six years later, a president from the same party hosted an Oval Office ceremony for psychedelic research.
• Peter Thiel (Founders Fund) and Antonio Gracias (Valor Equity Partners) are named among key backers of the psychedelic industry's political push. Neither has a background in clinical research.
• Ketamine/esketamine (Spravato): FDA approved 2019, $800+ per session, clinic-administered, proprietary delivery format — the existing legal template for what a fully medicalized psychedelic market looks like.
• August 2024: FDA rejects Lykos Therapeutics' MDMA-assisted therapy application — the most clinically validated psychedelic therapy in the pipeline — on trial design grounds, not efficacy. Lykos's valuation collapses. Investment in less-validated, more IP-protected compounds continues.
• Breakthrough Therapy designation is held by a small number of well-capitalized companies. The EO's regulatory fast lane accelerates their path, specifically, not the broader research community.

What to Watch Next

The most important data points over the next 12–18 months will not be in the executive order. They will be in the patent filings, the clinical trial registrations, and the insurance reimbursement negotiations. Watch for which companies move fastest through the accelerated FDA pathway. Watch for who ends up on the HHS advisory panels shaping the clinical guidelines. Watch for whether the therapy model that emerges looks more like ketamine infusion clinics (proprietary, expensive, scalable) or more like the MAPS model (therapist-administered, relationship-based, not easily monetized at scale).

And watch for the Lykos story. The organization that did the foundational MDMA research is now a biopharma company with a collapsed valuation, trying to resubmit to an FDA that has a faster lane for its competitors. How that plays out will tell you more about what this policy actually does than any White House press release.

Read next:

•  The New Space Race Is Mostly a Subsidy Story  — another industry that discovered libertarian politics the moment it needed federal money
•  Wellness Grifts: The Business Model Behind Detox  — same playbook, different molecules
•  How 'Common Knowledge' Gets Manufactured  — on the mechanics of the consensus being built around psychedelic therapy right now

Sources

• Trump Executive Order on Psychedelic Drug Research, April 18, 2026. White House.
• Andrew Jacobs, "A Long, Strange Trip: How the G.O.P. Came to Embrace Psychedelic Drugs." The New York Times, May 3, 2026. [Source for Nixon 1970 quote, ibogaine as veteran entry point, Oval Office ceremony details, Trump teetotaler detail, and DOJ marijuana loosening.]
• I. Glenn Cohen and Mason Marks, "Trump's Psychedelics Executive Order: What Does It Actually Do?" Harvard Petrie-Flom Center, April 18, 2026.
• Neşe Devenot, Chemical Poetics / Psymposia, April 2026. [Analysis of oligarchic investment in psychedelic medicine and the ideological dimensions of the right's pivot.]
• FDA Advisory Committee Meeting, Lykos Therapeutics MDMA-assisted therapy for PTSD, August 2024. Public record.
• Janssen Pharmaceuticals, Spravato (esketamine) prescribing information. FDA.gov.